17
Jan

A panel of FDA advisers voted 10-0 against recommending that Johnson & Johnson’s Xarelto be approved to treat patients with acute coronary syndrome, marking the third such rejection for the treatment.

…read more

Source: FDA panel shakes off J&J’s hopes of broader Xarelto use

    

0 No comments